50.10

3.72% 1.765

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$48.34

Aprire:

$47.85

Volume 24 ore:

1.60M

Relative Volume:

0.74

Capitalizzazione di mercato:

$8.35B

Reddito:

$1.56B

Utile/perdita netta:

$152.72M

Rapporto P/E:

55.71

EPS:

0.8994

Flusso di cassa netto:

$221.80M

1 W Prestazione:

-5.34%

1M Prestazione:

-4.30%

6M Prestazione:

+47.95%

1 anno Prestazione:

+79.52%

Intervallo 1D:

$47.71

$50.32

Intervallo di 1 settimana:

$47.66

$53.88

Portata 52W:

$25.16

$55.67

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1080)

Industria

Drug Manufacturers - Specialty & Generic (87)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

2,050

Cinguettio

@alkermes

Prossima data di guadagno

2026-07-28

Ultimi documenti SEC

ALKS's Discussions on Twitter

Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	50.11	8.79B	1.56B	152.72M	221.80M	0.8994
TAK Takeda Pharmaceutical Co Adr	17.21	55.69B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	10.07	43.77B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.41	36.19B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.85	32.25B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	525.06	26.29B	3.17B	1.29B	1.01B	27.09

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-06-29	Downgrade	BofA Securities	Neutral → Underperform
2026-02-24	Iniziato	Wolfe Research	Outperform
2025-11-11	Iniziato	Truist	Buy
2025-09-26	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Iniziato	Wells Fargo	Overweight
2025-07-15	Iniziato	Goldman	Buy
2025-06-17	Aggiornamento	UBS	Neutral → Buy
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

Jul 28, 2026

ALKS: Strong Q2 revenue, robust orexin pipeline progress, and LUMRYZ integration drive growth - TradingView

Jul 28, 2026

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down - Zacks Investment Research

Jul 28, 2026

Piper Sandler raises Alkermes stock price target on pipeline value - Investing.com

Jul 28, 2026

Alkermes Q2 Earnings Call Highlights - Yahoo Finance

Jul 28, 2026

Alkermes Q2 2026 slides: revenue surges 27% but acquisition costs squeeze - Investing.com

Jul 28, 2026

Earnings call transcript: Alkermes tops Q2 2026 estimates but shares fall premarket - Investing.com

Jul 28, 2026

ALKS Looks 64.8% Overvalued on GF Value™ - GuruFocus

Jul 28, 2026

Alkermes plc. Q2 2026: Revenue $496M, EPS $0— 10-Q Summary - TradingView

Jul 28, 2026

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance

Jul 28, 2026

Avadel deal pushes Alkermes (NASDAQ: ALKS) to H1 2026 net loss - Stock Titan

Jul 28, 2026

Why is Alkermes stock sliding today? - Investing.com

Jul 28, 2026

Piper Sandler raises Alkermes stock price target on pipeline value By Investing.com - Investing.com Canada

Jul 28, 2026

Earnings Flash (ALKS) Alkermes Public Company Posts Q2 EPS Breakeven, vs. FactSet Est of $0.03 Loss - marketscreener.com

Jul 28, 2026

Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M - TradingView

Jul 28, 2026

Alkermes Q2 Revenue Rises to $496 Million as CEO Transition Nears - Quiver Quantitative

Jul 28, 2026

Alkermes plc Reports Second Quarter 2026 Financial Results - Yahoo Finance

Jul 28, 2026

Jul 27, 2026